Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IWY9
UPID:
CDAN1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IWY9; Q6NYD0; Q7Z7L5; Q969N3
Background:
Codanin-1, encoded by the gene with accession number Q8IWY9, plays a crucial role in cellular processes by acting as a negative regulator of ASF1 in chromatin assembly. This regulation is vital for maintaining the integrity of genetic information during cell division and differentiation. The protein's unique structure, characterized by its ability to interact with various components of the chromatin assembly pathway, positions Codanin-1 as a key player in cellular homeostasis.
Therapeutic significance:
The association of Codanin-1 with congenital dyserythropoietic anemia, type 1A, underscores its clinical importance. This autosomal recessive blood disorder highlights the protein's pivotal role in erythropoiesis and iron metabolism. Understanding the role of Codanin-1 could open doors to potential therapeutic strategies aimed at correcting the underlying genetic defects, thereby offering hope for patients suffering from this and potentially related disorders.